Pharma BD Deal Intelligence
A $130M cancer metabolism collaboration that spawned an entirely new drug class. Celgene and Agios produced ivosidenib (Tibsovo) and enasidenib (Idhifa)—the first targeted therapies for IDH-mutant cancers. Downstream value multiplied as Servier later acquired the franchise for $2B.
Celgene / Agios (expanded collaboration): Achieved Stated Rationale (Score: 85/100)
Full analysis, sources & comparables →Agios and Celgene cancer metabolism agreement extended with additional $20 million as collaboration yields promising IDH inhibitor candidates
As part of the deal, Celgene will pay Agios $200 million upfront in cash, with various milestone payments possible. For the metabolic immuno-oncology programs,…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Celgene and Agios entered a three-year global strategic collaboration to discover and develop therapies targeting cancer cell metabolism, including IDH1 and IDH2 mutant inhibitors. Agios received $130 million upfront (including an equity investment). Celgene gained exclusive options to license clinical candidates emerging from the collaboration after Phase I. Each optioned program carried up to $120 million in milestones plus royalties. This deal ultimately led to the development of ivosidenib (Tibsovo/IDH1 inhibitor) and enasidenib (Idhifa/IDH2 inhibitor). Rights were later restructured: Celgene retained worldwide enasidenib rights; Agios regained US ivosidenib rights in 2016 amendments, with Celgene keeping ex-US option.
Celgene / Agios (expanded collaboration): Achieved Stated Rationale (Score: 85/100)
Assessment window: 5yr post-close.
Note: this deal's 5-year assessment window closes Apr 2015; the outcome grade above is a projected assessment, not yet finalized.
20K US cases/yr · $3.5B US IDH-Addressable Market (projected) · $2B Servier Acquisition of Agios Oncology (2021)
This record represents the broader Celgene-Agios cancer metabolism partnership including IDH inhibitors and metabolic targets across AML, cholangiocarcinoma, and glioma. The deal included $130M upfront plus equity for option rights on Agios's cancer metabolism pipeline.
The partnership produced two approved drugs (enasidenib 2017, ivosidenib 2018). Celgene was acquired by BMS in 2019 for $74B; BMS returned Agios rights. Servier acquired Agios oncology for $2B in 2021, continuing Tibsovo and Voranigo (vorasidenib) for glioma.
20K US cases/yr · $2.5B US AML Therapeutics Market (2010) · ~20% IDH1/2 Mutation Frequency in AML
Acute myeloid leukemia is an aggressive blood cancer with ~20,000 new US cases annually. Approximately 20% harbor IDH1 or IDH2 mutations. The Celgene-Agios collaboration yielded ivosidenib (Tibsovo, IDH1) and enasidenib (Idhifa, IDH2), both FDA-approved for relapsed/refractory IDH-mutant AML.
Enasidenib (Idhifa) received FDA approval in 2017, ivosidenib (Tibsovo) in 2018. Agios was acquired by Servier (2021) for $2B. Ivosidenib expanded into cholangiocarcinoma (2021) and frontline AML, establishing IDH inhibition as a precision oncology paradigm.
8K US cases/yr · $500M US Cholangiocarcinoma Market (2010) · ~15% IDH1 Mutation Rate in iCCA
Intrahepatic cholangiocarcinoma is a rare, aggressive malignancy with ~8,000 new US cases annually. Approximately 15% harbor IDH1 mutations. Ivosidenib was approved for IDH1-mutant cholangiocarcinoma in 2021.
In 2010, cholangiocarcinoma had no targeted therapies. Ivosidenib's ClarIDHy Phase III trial demonstrated PFS benefit. The biliary tract landscape later expanded with pemigatinib (FGFR2, 2020), futibatinib (FGFR2, 2022), and durvalumab+chemo (2022).
Celgene Corporation closes licensing/option of Agios Pharmaceuticals Inc. for $130M, establishing strategic position and initiating integration.
Strategic Fit: 90/100 | Financial Return: 80/100 | Pipeline Outcome: 88/100 | Integration: 72/100 | Deal Difficulty: 60/100. Achieved Stated Rationale overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Agios Pharmaceuticals Inc. (this deal) | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
| Celgene Corporation / Gloucester Pharmaceuticals, Inc. | 2009 | $640M | 40 |
← Browse all deals · How we score deals
More: 2010 deals · Celgene Corporation deals · Oncology deals